The PBS will subsidise brentuximab vedotin (Adcetris) for treatment of cutaneous T-cell lymphomas (CTCL) from 1 April. The listing is expected to benefit about 60 patients per year who would otherwise pay up to $300,000 a year for this treatment. The subsidy was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC), which concluded in November ...
Brentuximab vedotin is PBS listed for CTCL
By Michael Woodhead
20 Mar 2019